JSL
VRTX icon

JT Stratford LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

JT Stratford LLC’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.82M Sell
4,082
-12
-0.3% -$5.6K 0.23% 102
2025
Q4 		$1.86M Buy
4,094
+119
+3% +$51.3K 0.24% 92
2025
Q3 		$1.56M Buy
3,975
+161
+4% +$67.3K 0.21% 101
2025
Q2 		$1.7M Sell
3,814
-98
-3% -$45.2K 0.26% 86
2025
Q1 		$1.9M Sell
3,912
-44
-1% -$20.5K 0.34% 69
2024
Q4 		$1.59M Sell
3,956
-4,942
-56% -$2.29M 0.26% 88
2024
Q3 		$4.14M Buy
8,898
+17
+0.2% +$8.17K 0.71% 26
2024
Q2 		$4.16M Buy
8,881
+211
+2% +$91.6K 0.77% 25
2024
Q1 		$3.62M Buy
8,670
+2,107
+32% +$891K 0.72% 26
2023
Q4 		$2.67M Buy
6,563
+450
+7% +$166K 0.61% 34
2023
Q3 		$2.13M Buy
6,113
+1,407
+30% +$492K 0.55% 39
2023
Q2 		$1.66M Buy
4,706
+3,158
+204% +$1.06M 0.45% 61
2023
Q1 		$488K Buy
1,548
+212
+16% +$63.6K 0.14% 154
2022
Q4 		$386K Buy
1,336
+54
+4% +$16.5K 0.12% 159
2022
Q3 		$371K Sell
1,282
-79
-6% -$22.7K 0.13% 130
2022
Q2 		$384K Buy
+1,361
New +$364K 0.12% 148

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

JT Stratford LLC's VRTX Position: Q1 2026 in Review

JT Stratford LLC reduced its Vertex Pharmaceuticals (VRTX) stake by 0.29% in Q1 2026, selling an estimated $5.6K and leaving 4,082 shares worth $1.82M. The position accounts for 0.23% of the portfolio, ranked #102.

JT Stratford LLC first reported a position in VRTX in Q2 2022 and has held it in 16 quarters since. The position peaked at $4.16M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • JT Stratford LLC held 4,082 shares of Vertex Pharmaceuticals worth $1.82M as of Q1 2026.
  • JT Stratford LLC sold 12 Vertex Pharmaceuticals shares in Q1 2026, an estimated $5.6K.
  • Vertex Pharmaceuticals made up 0.23% of JT Stratford LLC's portfolio in Q1 2026, its #102 holding.
  • JT Stratford LLC first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
  • JT Stratford LLC's Vertex Pharmaceuticals position peaked at $4.16M in Q2 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on JT Stratford LLC's 13F filing for Q1 2026, filed 15 May 2026.